Sanofi

An R&D driven, AI-powered biopharma company committed to improving lives and delivering compelling growth. Terms for interactions:

[Sanofi @sanofi]

The @US_FDA granted accelerated approval for a treatment for #Type1Diabetes. Learn more: https://t.co/T7dMsW67eA

[Sanofi @sanofi]

#NEWS: Update on our phase 3 clinical study in chronic inflammatory demyelinating polyneuropathy (CIDP).

Learn more ⬇️

https://t.co/G12CzYjKyz

[Sanofi @sanofi]

With the approval from the @EU_Commission, our subcutaneous multiple myeloma (MM) therapy is now authorized across all existing IV indications for MM in the EU.

Read more: https://t.co/jx2wfCvl6A

[VivaTech @VivaTech]

From discovery to delivery, @Sanofi is using #AI to make a real impact🚀
At #VivaTech 2026, see how Sanofi uses AI to deliver faster for patients across R&D, manufacturing & supply & more. Plus, Sanofi & partners will share how AI & quantum tools are driving next‑gen innovation.

[Sanofi @sanofi]

#NEWS: The @US_FDA has granted priority review to our new drug application for an investigational oral molecule for type 3 Gaucher disease. Learn more: https://t.co/FT2fAMq4XZ

[Sanofi @sanofi]

Phase 2 data for our investigational treatment for #AATD presented for the first time at #ATS; These findings demonstrate our commitment to advancing innovation for people living with this rare disease. Learn more: https://t.co/HzlLsb4QAM

[VivaTech @VivaTech]

🔬@Sanofi teams are chasing the miracles of science to improve people’s lives.

As an R&D‑driven, AI‑powered biopharma company, they’ll show how scaled AI & digital innovation accelerate breakthrough medicines & vaccines for people globally.

Find them at #VivaTech 2026🚀

[Sanofi @sanofi]

"Hi @okuyucu159, we’re unable to discuss medicines and other products on social media but you can send us your questions via the contact form on our website: https://t.co/UeGiVavrdO.

If you have questions or concerns about your health, please talk to your healthcare provider.

Thanks,
Sanofi Social Media Team"

[Sanofi @sanofi]

#NEWS: The @EMA_News CHMP has recommended for approval our new investigational treatment for secondary progressive #multiplesclerosis without relapses, reinforcing our commitment to advance scientific innovation that address unmet patient needs.

Learn more ⬇️https://t.co/JDmesFNi6s

[Sanofi @sanofi]

Our Q1 2026 results are now available.
See the press release for more details: https://t.co/McL3v5nR1p

#SanofiResults $SAN $SNY

[Sanofi @sanofi]

The @US_FDA has approved our medicine for certain children aged 2-11 years with uncontrolled chronic spontaneous urticaria (CSU). ➡️ Read more: https://t.co/oACqL4ufQ2

CC: @Regeneron

[Sanofi @sanofi]

The @US_FDA has approved a treatment for eligible young children with #Type1Diabetes. With this approval, we hope to better support these young T1D patients and their families. Learn more: https://t.co/TJBx2YPZ4K

[Sanofi @sanofi]

#NEWS: COMPARE study presented at #ESCMIDGlobal2026: head-to-head tolerability comparison of a protein-based and an mRNA COVID-19 vaccine

Read our press release: https://t.co/p08Lp168MU

[Sanofi @sanofi]

The @EU_Commission has approved our medicine in the EU for the treatment of chronic spontaneous urticaria (CSU) in certain children aged 2 to 11 years. More information here ➡️: https://t.co/PKsJHEwqIs

CC: @Regeneron

[Sanofi @sanofi]

#NEWS: Positive results from two Phase 2 studies evaluating our investigational treatment in #Asthma and #CRSwNP, demonstrating potential for people living with chronic respiratory conditions.

Learn more ⬇️
https://t.co/vfqXmgYL6f

[Sanofi @sanofi]

The @EU_Commission has approved our medicine for the treatment of chronic graft-versus-host disease (GVHD) in certain adults and children aged 12 years and older, providing a new treatment mechanism for eligible patients with limited therapeutic options. Learn more: https://t.co/5q1AQJJu3G

[Sanofi @sanofi]

We presented late-breaking research on our investigational medicine for moderate-to-severe atopic dermatitis patients at #AAD2026. Learn more about our findings: https://t.co/2mDgXho1Aj

[Sanofi @sanofi]

The @EMA_News CHMP recommended approval of our subcutaneous therapy administered via an innovative delivery method for patients across the #MultipleMyeloma (MM) spectrum in the EU.

If approved, this therapy would represent a significant step for the MM community.

Read more: https://t.co/EigDRMzWMs

[Sanofi @sanofi]

Japan’s Ministry of Health, Labour and Welfare has approved our medicine for certain adults with bullous pemphigoid (BP). Read more: https://t.co/7zflMsuwna

CC: @Regeneron